Cargando…
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
The requirement for bone-marrow aspirates for genomic profiling of multiple myeloma poses an obstacle to enrolment and retention of patients in clinical trials. We evaluated whether circulating cell-free DNA (cfDNA) analysis is comparable to molecular profiling of myeloma using bone-marrow tumour ce...
Autores principales: | Kis, Olena, Kaedbey, Rayan, Chow, Signy, Danesh, Arnavaz, Dowar, Mark, Li, Tiantian, Li, Zhihua, Liu, Jessica, Mansour, Mark, Masih-Khan, Esther, Zhang, Tong, Bratman, Scott V., Oza, Amit M., Kamel-Reid, Suzanne, Trudel, Suzanne, Pugh, Trevor J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437268/ https://www.ncbi.nlm.nih.gov/pubmed/28492226 http://dx.doi.org/10.1038/ncomms15086 |
Ejemplares similares
-
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing
por: Chow, Signy, et al.
Publicado: (2022) -
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
por: Yang, S. Y. Cindy, et al.
Publicado: (2018) -
P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023) -
Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression
por: Croucher, Danielle C., et al.
Publicado: (2023) -
Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient
por: Colombo, Ilaria, et al.
Publicado: (2019)